查看文章

Background

Immune checkpoint inhibitors are standard of care in recurrent/metastatic SCCHN. We evaluated concurrent radioimmunotherapy (RIT) with Nivo and Ipi in the definitive setting for patients with high-risk LA SCCHN.

Methods

Pts with newly diagnosed, AJCC 7th edition stage IVA-IVB SCCHN of the oropharynx (OP; OP HPV+ were T4, N2c or N3), hypopharynx, and larynx that were eligible for chemotherapy received Nivo (3 mg/kg Q2 weeks x 17) and Ipi (1 mg/kg Q6 weeks x 6) starting 2 weeks prior to IMRT (2 Gy/fraction/day to a total of 70 Gy). The primary endpoint was safety of RIT. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). Exploratory endpoints included the association of baseline PD-L1 expression as well as on-treatment changes in immune bias with treatment outcomes.

Results

24 pts (16 OP of whom 14 HPV+) were enrolled and followed for a median of …